Advinus Therapeutics, a research-based pharmaceutical development company promoted by the TATA Group, and SignalChem Pharmaceuticals, a British Columbia-based drug discovery company, have started working on 15 programs based on SignalChem’s proprietary Kinase platform for targeted therapies in oncology. Each program is being developed with corresponding diagnostics and tracers for patient selection and biomarkers for follow up offering the right treatment to the right patient at the right time. The companies have received a very high level of interest from pharma companies to license and collaborate on the programs and therefore see a rapid progression to the clinic.

Dr. Rashmi Barbhaiya, CEO and MD of Advinus said– “This collaboration is an exemplary model of polycentric and globally networked innovation for enhancing probability of success, reducing timelines, and focusing on cost-effective partnerships to bring innovative medicines to the market. This collaboration would also leverage leading edge biomedical research of British Columbia research institutions and Advinus’s capabilities and infrastructure to translate biomedical research discoveries into potential life saving drugs.”

Dr. Jasbinder Sanghera, CEO of SignalChem said – “This is a path-breaking partnership that leverages SignalChem’s extensive biology and kinase expertise and Advinus’s end-to-end capabilities of medicinal chemistry, lead optimization, preclinical development and early-clinical development capabilities to rapidly and efficiently advance new anti-cancer drug candidates into human clinical trials.”

The collaboration was announced by B.C. Premier Christy Clark during her visit to India who said – “This is what our Jobs Trade Mission is all about – helping local companies make connections that will allow them to do business in India. We have an innovative technology and life sciences sector in B.C., which has a lot to offer India to support its economic growth. The partnership between Advinus and SignalChem will benefit people around the world.”

Via EPR Network
More Biotech press releases